|
|
|
|
No difference in mortality or neurological outcome was found with any of the rating scales for the overall cohort.Planned but post hoc subgroup analysis showed a reduction in worsening frequency of 30%compared with placebo and significantly better outcome scores with 120 mg nimodipine daily started within 18 hours of stroke as measured by the Toronto scale (p<0.005)and when the pretreatment computed tomographic scan was negative (p<0.003).Conclusions:Nimodipine had no overall effect when treatment was begun within 48 hours.Confirmation of the benefits suggested by post hoc analyses for the subgroup treated with 120 mg nimodipine within 18 hours, and who had negative computed tomographic scans,would require a separate trial. |
|